- Trials with a EudraCT protocol (140)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
140 result(s) found for: Weighted mean.
Displaying page 3 of 7.
EudraCT Number: 2014-000611-14 | Sponsor Protocol Number: 201314 | Start Date*: 2014-06-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive P... | |||||||||||||
Medical condition: in subjects with Chronic Obstructive Pulmonary Disease COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023418-29 | Sponsor Protocol Number: HZC113109 | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: HZC113109: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022073-34 | Sponsor Protocol Number: PST2238-DM-10-001 | Start Date*: 2010-12-29 | |||||||||||
Sponsor Name:CVIE THERAPEUTICS COMPANY LIMITED | |||||||||||||
Full Title: Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according t... | |||||||||||||
Medical condition: Patients with arterial hypertension, bearers of a specific genetic profile (Presence of at least one mutated genotype or combination of genotypes corresponding to the list provided in Genetic Profi... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003409-33 | Sponsor Protocol Number: AllopurinolALL3.1 | Start Date*: 2016-12-09 |
Sponsor Name:Västra Götaland Regionen | ||
Full Title: Optimizing 6-mercaptopurine therapy in pediatric acute lymphoblastic leukemia by using allopurinol. Clinical study in children 1-19 years on maintenance therapy for acute lymphoblastic leukemia. | ||
Medical condition: Acute lymphoblastic leukemia diagnosed at age 0-18 in children | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002451-33 | Sponsor Protocol Number: HZC115805 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tio... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005817-23 | Sponsor Protocol Number: 8245-005 | Start Date*: 2008-12-24 | |||||||||||
Sponsor Name:Merck & Co., Inc | |||||||||||||
Full Title: A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000477-21 | Sponsor Protocol Number: 01579 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||
Full Title: Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial | |||||||||||||
Medical condition: uncomplicated urinary tract infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002691-18 | Sponsor Protocol Number: CBA106809 | Start Date*: 2006-10-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 receptor agonist, on p... | |||||||||||||
Medical condition: Inflammatory Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) IT (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014344-11 | Sponsor Protocol Number: prot-001-2009 | Start Date*: 2010-06-02 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial | |||||||||||||
Medical condition: Neonatal asphyxial encephalopathy | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000215-22 | Sponsor Protocol Number: HH3104994 | Start Date*: 2006-02-08 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A randomised, double blind, placebo controlled, two-way crossover, three phase, study, to investigate the trial models, Vienna Challenge Chamber, in and out of season, and Park Study in season and ... | ||
Medical condition: Seasonal Allergic Rhinitis (SAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003004-19 | Sponsor Protocol Number: BILA-2306/ACC | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:FAES Farma S.A. | |||||||||||||
Full Title: A randomised, double-blind, four way cross-over, placebo controlled trial to evaluate the clinical efficacy, onset of action and drug activity at 22-26 hours following the drug intake of Bilastne 2... | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003492-35 | Sponsor Protocol Number: MED2-201301 | Start Date*: 2015-05-26 |
Sponsor Name:University of Bonn | ||
Full Title: Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation | ||
Medical condition: atrial fibriallation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-001554-25 | Sponsor Protocol Number: 371 | Start Date*: 2019-10-29 |
Sponsor Name:Reade | ||
Full Title: Adalimumab dose optimization in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-center single blinded randomized controlled trail | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000832-23 | Sponsor Protocol Number: KH176-203 | Start Date*: 2021-07-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutatio... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001735-49 | Sponsor Protocol Number: CTU/2015/174 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial | |||||||||||||
Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001419-30 | Sponsor Protocol Number: AC2105333 | Start Date*: 2006-08-07 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233... | ||
Medical condition: Study is in COPD patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004481-16 | Sponsor Protocol Number: VRA105345 | Start Date*: 2005-12-19 |
Sponsor Name:GlaxoSmithKline Research and Development | ||
Full Title: A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar too... | ||
Medical condition: Dental pain | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004476-12 | Sponsor Protocol Number: NCHECR001 | Start Date*: 2007-07-10 | |||||||||||
Sponsor Name:University of New South Wales | |||||||||||||
Full Title: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. | |||||||||||||
Medical condition: Chronic HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IE (Completed) DE (Ongoing) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019465-28 | Sponsor Protocol Number: HZA113126 | Start Date*: 2010-06-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on... | |||||||||||||
Medical condition: subjects with mild asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001516-11 | Sponsor Protocol Number: 201832 | Start Date*: 2017-07-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Ad... | |||||||||||||
Medical condition: Adolescent and Adult Subjects with Asthma and Exercise-Induced Bronchoconstriction | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
